Skip to content
DataLookout
Menu

NCT07920679

Efficacy and Safety of K-CAB(Tegoprazan) 25 mg as Maintenance Therapy Following the Treatment of GERD

StatusRecruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Study title shortened, about 10 words
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

The proportion of study participants with a Korean Gastroesophageal Reflux Disease Questionnaire (GerdQ) score below 8 at Week 24 after administration of K-CAB Tab/K-CAB ODT 25 mg
Timeframe: At Week 24 after enrollment

Sites

1 site in 1 country

  • HK inno.NSeoul, South Korea